Tarsus Pharmaceuticals (TARS) Raw Materials (2023 - 2024)

Tarsus Pharmaceuticals (TARS) posted quarterly Raw Materials of $2.5 million for Q1 2024, little changed quarter-over-quarter from $2.5 million in Q4 2023.

Tarsus Pharmaceuticals (TARS) Raw Materials (2023 - 2024) Analysis & Trends

Tarsus Pharmaceuticals' Raw Materials history runs 2 years deep, the most recent figure standing at $2.5 million for Q1 2024.

  • In Q1 2024, Raw Materials changed N/A year-over-year to $2.5 million; the TTM figure through Mar 2024 stood at $2.5 million (changed N/A YoY), while the FY2023 annual figure was $2.5 million, changed N/A from the prior year.
  • Raw Materials for Q1 2024 stood at $2.5 million, roughly flat from $2.5 million in the prior quarter.
  • The five-year high for Raw Materials was $2.5 million in Q4 2023, with the low at $2.5 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Tarsus Pharmaceuticals 2.99 Bn 2.54 Bn 161.80 Mn

Historic Data

Download Data
DateValue
Mar 31, 2024 2.53 Mn
Dec 31, 2023 2.53 Mn